ifenprodil has been researched along with Idiopathic Pulmonary Fibrosis in 1 studies
ifenprodil: NMDA receptor antagonist
Idiopathic Pulmonary Fibrosis: A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bechthold, E | 1 |
| Schreiber, JA | 1 |
| Lehmkuhl, K | 1 |
| Frehland, B | 1 |
| Schepmann, D | 1 |
| Bernal, FA | 1 |
| Daniliuc, C | 1 |
| Álvarez, I | 1 |
| Garcia, CV | 1 |
| Schmidt, TJ | 1 |
| Seebohm, G | 1 |
| Wünsch, B | 1 |
1 other study available for ifenprodil and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.
Topics: Antifibrinolytic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Crystallography, X-Ray | 2021 |